Merck Stock: Shares Bucking The Gardasil Problem, Hiking My Price Target (NYSE:MRK)

Merck’s strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns. See why MRK stock is a buy.